James Mackay, Aristea Therapeutics president and CEO
February 10, 2023 10:03 AM EST
People
R&D

Aris­tea shut­ters, end­ing hopes of a Pfiz­er buy­out

Kyle LaHucik

Senior Reporter

As­traZeneca spin­out Aris­tea Ther­a­peu­tics is shut­ting down af­ter ter­mi­nat­ing mul­ti­ple Phase II stud­ies of its in­flam­ma­to­ry drug, cit­ing undis­closed safe­ty is­sues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times